Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial
Articolo
Data di Pubblicazione:
2020
Abstract:
https://www.ncbi.nlm.nih.gov/pubmed/32343462
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
*genetic and inherited disorders
Elenco autori:
Brannagan, T. H.; Wang, A. K.; Coelho, T.; Waddington Cruz, M.; Polydefkis, M. J.; Dyck, P. J.; Plante-Bordeneuve, V.; Berk, J. L.; Barroso, F.; Merlini, G.; Conceicao, I.; Hughes, S. G.; Kwoh, J.; Jung, S. W.; Guthrie, S.; Pollock, M.; Benson, M. D.; Gertz, M.; Investigators, Neuro-Ttr open-label extension
Link alla scheda completa:
Pubblicato in: